G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023
Shots:
- At the data cut-off on Apr 2023, 30 patients received 1 dose of any study drug, 93.3% had metastatic disease with a median of 5.5 cycles of treatment, and the median follow-up was 5.5mos., 11 remaining on study treatment & 22 in the study
- 73.3% & 63.3% had received prior PD-(L)1 immunotherapy incl. a heavily pretreated patient population & PD-L1(+) tumors. On-target effect of trilaciclib reduces rates of multiple AEs associated with sacituzumab govitecan-hziy by ~50%, TRAE of any grade related to any study drug (76.7%)
- Initial results showed ORR (35.3%) in patients with PD-L1(+) mTNBC vs 25.0% in an overall study population, 1 additional patient experienced an unconfirmed response, m-PFS with trilaciclib + sacituzumab was 4.1mos. OS results are expected in Q1’24
Ref: G1 Therapeutics | Image: G1 Therapeutics
Related News:- G1 Therapeutics Reports P-III Trial (PRESERVE 1) Results of Trilaciclib for Metastatic Colorectal Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
